Wednesday, April 17, 2013

Cipla launches first Biosimilar of etanercept in India under brand name ‘ETACEPT

Cipla, the fifth largest pharma company in India with consolidated net sales of Rs.6,800 crore plus, has launched the first biosimilar of Etanercept in India; under the brand name ‘ETACEPT’ for the treatment of rheumatic disorders. Formed through a partnership alliance, ETACEPT is manufactured by a China-based company Shanghai CP Guojian Pharmaceutical Co. Ltd., which will be marketed by Cipla in India.


Etacept is available as a lyophilized powder to be given by subcutaneous injection. It is available with stockists across the country at Rs.6,150 and the recommended dose for adults is 25mg twice weekly by subcutaneous injection.

The higher cost of biologics has been a major hindrance, limiting its affordability and accessibility to millions of patients.Etacept has been priced at a lower cost (30 per cent lesser as compared to the innovator) and should enable access of this drug to a greater number of patients in India. The accessibility of this drug may be further enahnced if we consider the results of a recent study that showed in patients who were successfully treated with Etanercept for six months, a 50 per cent reduced dose worked just as well as continuing the current dose.


Enter your email address:


Delivered by FeedBurner